Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research

News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971

VIDEO: BioNTech CBO Outlines Infectious Disease Ambitions

Thu, 11/29/2018 - 2:27am

German mRNA-focused biotech BioNTech is branching out from its immuno-oncology focus to explore the potential of its platforms in infectious...

      Related Stories 

Pharma CEO Pay Up In India, Ratio Versus Employee Earnings Glaring

Wed, 11/28/2018 - 6:01pm

Pharma CEOs in India took home higher remuneration in 2017-18, with experts suggesting that the upward trend isn’t entirely unexpected...

      Related Stories 

ASH Preview: Practice-Changing Darzalex And Imbruvica, Advances In Beta-Thalassemia And More

Wed, 11/28/2018 - 5:08pm

Late-breaker presentations for Darzalex in multiple myeloma and Imbruvica in CLL will showcase "practice-changing" results in front-line settings. Other highlights...

      Related Stories 

Breast Cancer, HIV Drugs May Face Tougher Part D Climate Under Protected Class Proposal

Tue, 11/27/2018 - 1:41pm

Medicare proposed rule exposes Part D protected class drugs to threat of formulary exclusion if price increases exceed a certain...

      Related Stories 

Teva Launches Generic EpiPen At Same Price As Mylan's Generic

Tue, 11/27/2018 - 11:38am

Teva's epinephrine will be the first alternative to branded and authorized generics made by Mylan, but the wholesale acquisition cost...

      Related Stories 

BMS SCLC Chances Dive After Opdivo, Yervoy Combo Flunks Checkmate-451

Tue, 11/27/2018 - 6:44am

BMS's Phase III Checkmate-451 combo trial with Opdivo and Yervoy misses its endpoint for small cell lung cancer in overall...

      Related Stories 

FDA Nod For Loxo/Bayer Tissue Agnostic Drug Marks Paradigm Shift In Cancer

Tue, 11/27/2018 - 6:42am

Vitrakvi is effective against a wide variety of cancers driven by NTRK fusion. Now the challenge is to actually find...

      Related Stories 

Adrenomed Treads A New Path In Septic Shock

Tue, 11/27/2018 - 6:37am

German firm Adrenomed has received new funding to push its innovative antibody for septic shock further into development. The company...

      Related Stories 

Can Modicare Reshape India’s Health Care Paradigm?

Tue, 11/27/2018 - 5:26am

India’s new government-funded health care program expects to expand access to treatment to more than 100 million families. Can it...

      Related Stories